{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:00:53Z","timestamp":1792051253738,"version":"4.4.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/ajg.2016.236","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T08:03:59Z","timestamp":1465891439000},"page":"1147-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":294,"title":["The Real-World Effectiveness and Safety of Vedolizumab for Moderate\u2013Severe Crohn\u2019s Disease: Results From the US VICTORY Consortium"],"prefix":"10.14309","volume":"111","author":[{"given":"Parambir S","family":"Dulai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Peerani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Chaudrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hudesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Lukin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Swaminath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Shmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigid S","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunanda","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210306","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohns diseasealgorithm for practical management.","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R2-21-20210306","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.gtc.2014.05.010","article-title":"The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease.","volume":"43","author":"Dulai","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"R3-21-20210306","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.","volume":"12","author":"Dulai","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-21-20210306","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/gutjnl-2014-307126","article-title":"Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD.","volume":"63","author":"Dulai","year":"2014","journal-title":"Gut"},{"key":"R5-21-20210306","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohns disease.","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"R7-21-20210306","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.mayocp.2014.08.019","article-title":"Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysis.","volume":"89","author":"Singh","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"R8-21-20210306","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/MIB.0000000000000661","article-title":"How will evolving future therapies and strategies change how we position the use of biologics in moderate to severely active inflammatory bowel disease.","volume":"22","author":"Dulai","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R9-21-20210306","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.","volume":"10","author":"Ha","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-21-20210306","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.gie.2015.03.1974","article-title":"Assessment of mucosal healing in inflammatory bowel disease: review.","volume":"82","author":"Dulai","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"R11-21-20210306","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/ajg.2015.326","article-title":"Pseudomonas meningitis during vedolizumab therapy for Crohns disease.","volume":"110","author":"Boland","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R13-21-20210306","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"R14-21-20210306","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R17-21-20210306","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohns disease.","volume":"7","author":"Schreiber","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R18-21-20210306","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort.","volume":"21","author":"Shelton","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R19-21-20210306","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjv226","article-title":"Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice.","volume":"10","author":"Vivio","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R20-21-20210306","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practicea nationwide consecutive German cohort study.","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-21-20210306","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohns disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R26-21-20210306","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohns disease in the SONIC trial.","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"R27-21-20210306","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-21-20210306","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/apt.13460","article-title":"A validated web-based tool to display individualised Crohns disease predicted outcomes based on clinical, serologic and genetic variables.","volume":"43","author":"Siegel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-21-20210306","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/apt.13511","article-title":"Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohns disease.","volume":"43","author":"To","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-21-20210306","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/ibd.21889","article-title":"Current smoking differentially affects blood mononuclear cells from patients with Crohns disease and ulcerative colitis: relevance to its adverse role in the disease.","volume":"18","author":"Bergeron","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R31-21-20210306","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.4049\/jimmunol.151.10.5172","article-title":"Differential induction of VCAM-1 on human iliac venous and arterial endothelial cells and its role in adhesion.","volume":"151","author":"Hauser","year":"1993","journal-title":"J Immunol"},{"key":"R32-21-20210306","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MIB.0b013e31828100a4","article-title":"Effect of tumor necrosis factor-alpha blockade on mucosal addressin cell-adhesion molecule-1 in Crohns disease.","volume":"19","author":"Biancheri","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R33-21-20210306","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1053\/j.gastro.2014.08.044","article-title":"Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.","volume":"147","author":"Danese","year":"2014","journal-title":"Gastroenterology"},{"key":"R34-21-20210306","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.crohns.2010.05.011","article-title":"Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.","volume":"4","author":"Chowers","year":"2010","journal-title":"J Crohns Colitis"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2016236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016236","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201608000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:12:57Z","timestamp":1786547577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201608000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2016.236","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}